219 related articles for article (PubMed ID: 28390927)
21. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
[TBL] [Abstract][Full Text] [Related]
22. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
Lara S; Heilig J; Virtanen A; Kleinau S
BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
[TBL] [Abstract][Full Text] [Related]
23. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
24. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
25. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
26. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
[TBL] [Abstract][Full Text] [Related]
27. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
28. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
29. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
30. Complement and cellular cytotoxicity in antibody therapy of cancer.
Wang SY; Weiner G
Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787
[TBL] [Abstract][Full Text] [Related]
31. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
32. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.
van Meerten T; Rozemuller H; Hol S; Moerer P; Zwart M; Hagenbeek A; Mackus WJ; Parren PW; van de Winkel JG; Ebeling SB; Martens AC
Haematologica; 2010 Dec; 95(12):2063-71. PubMed ID: 20851867
[TBL] [Abstract][Full Text] [Related]
33. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
[TBL] [Abstract][Full Text] [Related]
34. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.
Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA
Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988
[TBL] [Abstract][Full Text] [Related]
35. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.
Shiokawa M; Takahashi T; Murakami A; Kita S; Ito M; Sugamura K; Ishii N
Biochem Biophys Res Commun; 2010 Sep; 399(4):733-7. PubMed ID: 20696130
[TBL] [Abstract][Full Text] [Related]
36. Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
You T; Hu W; Ge X; Shen J; Qin X
Cell Mol Immunol; 2011 Mar; 8(2):157-63. PubMed ID: 21258360
[TBL] [Abstract][Full Text] [Related]
37. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
[TBL] [Abstract][Full Text] [Related]
38. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
40. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.
Teeling JL; French RR; Cragg MS; van den Brakel J; Pluyter M; Huang H; Chan C; Parren PW; Hack CE; Dechant M; Valerius T; van de Winkel JG; Glennie MJ
Blood; 2004 Sep; 104(6):1793-800. PubMed ID: 15172969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
